Manning & Napier Group's GILD Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 108,671 shares of Gilead Sciences, Inc. (GILD) worth $13.39 M, representing 0.17% of the portfolio. First purchased in 2017-Q2, this long-term strategic position has been held for 35 quarters.
Based on 13F filings, Manning & Napier Group has maintained a strategic position in GILD, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2019, adding 67,924 shares. Largest reduction occurred in Q3 2025, reducing 107,065 shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's Gilead Sciences (GILD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Gilead Sciences (GILD) Trades by Manning & Napier Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2017 | +214,432 | New Buy | 214,432 | $70.78 |
| Q3 2017 | -25,051 | Reduce 11.68% | 189,381 | $81.02 |
| Q4 2017 | +173,560 | Add 0.00% | 173,559 | $71.64 |
| Q1 2018 | +39,383 | Add 22.69% | 212,942 | $75.39 |
| Q2 2018 | +20,659 | Add 9.70% | 233,601 | $70.84 |
| Q3 2018 | +15,062 | Add 6.45% | 248,663 | $77.20 |
| Q4 2018 | +24,830 | Add 9.99% | 273,493 | $62.55 |
| Q1 2019 | +67,924 | Add 24.84% | 341,417 | $65.01 |
| Q2 2019 | +62,980 | Add 18.45% | 404,397 | $67.56 |
| Q3 2019 | +2,928 | Add 0.72% | 407,325 | $63.38 |
| Q4 2019 | +45,168 | Add 11.09% | 452,493 | $64.98 |
| Q1 2020 | -37,816 | Reduce 8.36% | 414,677 | $74.76 |
| Q2 2020 | +26,953 | Add 6.50% | 441,630 | $76.94 |
| Q3 2020 | -3,100 | Reduce 0.70% | 438,530 | $63.19 |
| Q4 2020 | -29,662 | Reduce 6.76% | 408,868 | $58.25 |
| Q1 2021 | +9,711 | Add 2.38% | 418,579 | $64.63 |
| Q2 2021 | +67,578 | Add 16.14% | 486,157 | $68.86 |
| Q3 2021 | -8,147 | Reduce 1.68% | 478,010 | $69.85 |
| Q4 2021 | -23,939 | Reduce 5.01% | 454,071 | $72.61 |
| Q1 2022 | -28,726 | Reduce 6.33% | 425,345 | $59.45 |
| Q2 2022 | -41,336 | Reduce 9.72% | 384,009 | $61.81 |
| Q3 2022 | -5,066 | Reduce 1.32% | 378,943 | $61.69 |
| Q4 2022 | -4,154 | Reduce 1.10% | 374,789 | $85.85 |
| Q1 2023 | -692 | Reduce 0.18% | 374,097 | $82.97 |
| Q2 2023 | +23,077 | Add 6.17% | 397,174 | $77.07 |
| Q3 2023 | -5,359 | Reduce 1.35% | 391,815 | $74.94 |
| Q4 2023 | -57,475 | Reduce 14.67% | 334,340 | $81.01 |
| Q1 2024 | -26,410 | Reduce 7.90% | 307,930 | $73.25 |
| Q2 2024 | +61,230 | Add 19.88% | 369,160 | $68.61 |
| Q3 2024 | -14,579 | Reduce 3.95% | 354,581 | $83.84 |
| Q4 2024 | -28,444 | Reduce 8.02% | 326,137 | $92.37 |
| Q1 2025 | -26,713 | Reduce 8.19% | 299,424 | $112.05 |
| Q2 2025 | -71,122 | Reduce 23.75% | 228,302 | $110.87 |
| Q3 2025 | -107,065 | Reduce 46.90% | 121,237 | $112.62 |
| Q4 2025 | -12,566 | Reduce 10.36% | 108,671 | $123.18 |
Manning & Napier Group's Gilead Sciences Investment FAQs
Manning & Napier Group first purchased Gilead Sciences, Inc. (GILD) in Q2 2017, acquiring 214,432 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held Gilead Sciences, Inc. (GILD) for 35 quarters since Q2 2017.
Manning & Napier Group's largest addition to Gilead Sciences, Inc. (GILD) was in Q2 2017, adding 214,432 shares worth $15.18 M.
According to the latest 13F filing for Q4 2025, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 108,671 shares of Gilead Sciences, Inc. (GILD), valued at approximately $13.39 M.
As of the Q4 2025 filing, Gilead Sciences, Inc. (GILD) represents approximately 0.17% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.
Manning & Napier Group's peak holding in Gilead Sciences, Inc. (GILD) was 486,157 shares, as reported at the end of Q2 2021.